Drug-eluting stents (DES) have been viewed as a fantastic advance above earlier stents and balloon angioplasty because they outcome in numerous fewer circumstances of restenosis. But enthusiasm for the 1st generation of DES was somewhat curbed due to reviews of late stent thrombosis (ST), a uncommon but really hazardous complication. Now findings from a big ongoing registry review supply some reassurance about the lengthy-term safety of the new generation of drug-eluting stents in patients with heart attacks (STEMI). The results are published in the Journal of the American University of Cardiology.
SCAAR (Swedish Coronary Angiography and Angioplasty Registry) investigators analyzed information from 34,000 primary PCI patients who received a bare-metal stent, an previous-generation DES, or a new-generation DES. They found that in the very first year right after PCI the two new- and old-generation DES individuals had a decrease danger of stent thrombosis (ST) than BMS individuals. Really late ST up to 3 many years was increased in the old-generation DES group in contrast to the two the new-generation DES and BMS groups, which had similar risks. At 1 yr the ST price was one.5% for BMS, one.one% for the previous-generation DES, and .9% for the new-generation DES. At 3 many years the charges have been 2%, two.1%, and 1.3%.
The new findings lend support to the widespread see that the new-generation DES would minimize the late danger of ST that has been previously observed with previous-generation DES. The most prominent makers of BMS and DES have been Medtronic Medtronic, Boston Scientific Boston Scientific, and Abbott.
Precise info about ST has been tough to get from randomized scientific studies, largely because the studies have been underpowered to detect these type of distinctions in the rate of rare but clinically crucial events.
In an accompanying editorial, Bradley Strauss and Mony Shuvy publish that the “results are reassuring and must mitigate concerns about late and very late ST with second-generation DES in STEMI sufferers.”
Commenting on the papers, L. David Hillis mentioned that “the registry’s dimension is remarkable and it appears that each the authors and the editorialists have mentioned the primary limitations with these information: (1) the possible choice bias that could enter into any nonrandomized trial and (2) the lack of any information about lengthy-phrase healthcare treatment, most importantly dual antiplatelet treatment.”
Research Delivers Reassurance About Newer Drug-Eluting Stents
Hiç yorum yok:
Yorum Gönder